{"id":28474,"date":"2026-03-09T19:07:21","date_gmt":"2026-03-09T19:07:21","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/28474\/"},"modified":"2026-03-09T19:07:21","modified_gmt":"2026-03-09T19:07:21","slug":"roche-stock-falls-as-breast-cancer-drug-fails-trial-goals","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/28474\/","title":{"rendered":"Roche Stock Falls as Breast Cancer Drug Fails Trial Goals"},"content":{"rendered":"<p>&#13;<\/p>\n<p>In a significant setback, Roche&#8217;s shares suffered a steep drop exceeding 7% at one point on Monday following the announcement that its breast cancer drug, giredestrant, did not pass a critical trial. The trial aimed to demonstrate that the drug, when paired with Pfizer&#8217;s Ibrance, could effectively slow disease progression compared to standard therapies, but it fell short.<\/p>\n<p>Despite the negative outcome, analysts like Barclays&#8217; James Gordon view the dip as a buying opportunity, pointing to the underrecognized potential of giredestrant as an adjuvant therapy. Previous studies showed promise when the drug was used as a second-line treatment, cutting the risk of tumor recurrence.<\/p>\n<p>However, Roche faces stiff competition with players like AstraZeneca entering the market with alternatives such as camizestrant. This trial&#8217;s results cast doubts on the optimistic projections surrounding giredestrant. Nonetheless, Roche remains committed, seeking approval from the U.S. Food and Drug Administration based on earlier successful trials.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; In a significant setback, Roche&#8217;s shares suffered a steep drop exceeding 7% at one point on Monday&hellip;\n","protected":false},"author":2,"featured_media":28475,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[14607,207,17245,9388,17051,3517,17060,134,3518,1424],"class_list":{"0":"post-28474","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-astrazeneca","9":"tag-breast-cancer","10":"tag-camizestrant","11":"tag-cancer-treatment","12":"tag-drug-trial","13":"tag-giredestrant","14":"tag-ibrance","15":"tag-roche","16":"tag-serd","17":"tag-stock-market"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116200789959341146","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=28474"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/28474\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/28475"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=28474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=28474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=28474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}